S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
S&P 500   3,094.04 (+0.07%)
DOW   27,783.59 (+0.33%)
QQQ   201.59 (+0.02%)
AAPL   264.47 (+1.02%)
FB   193.19 (-0.66%)
MSFT   147.31 (+0.16%)
GOOGL   1,296.18 (-0.08%)
AMZN   1,753.11 (-1.40%)
CGC   18.50 (-3.90%)
NVDA   208.57 (-0.50%)
MU   46.30 (-1.28%)
BABA   182.48 (-2.40%)
GE   11.29 (-1.14%)
TSLA   346.11 (-1.09%)
T   39.16 (-0.03%)
AMD   37.52 (+2.21%)
F   8.81 (-2.54%)
ACB   3.55 (-0.56%)
PRI   128.60 (-1.04%)
NFLX   283.11 (-3.05%)
BAC   32.79 (-0.91%)
GILD   63.33 (-1.54%)
DIS   148.72 (+7.32%)
Log in

Aimmune Therapeutics Stock Price, Forecast & Analysis (NASDAQ:AIMT)

$27.57
-0.75 (-2.65 %)
(As of 11/13/2019 04:00 PM ET)
Today's Range
$27.20
Now: $27.57
$28.24
50-Day Range
$20.53
MA: $25.38
$29.58
52-Week Range
$16.95
Now: $27.57
$31.83
Volume870,300 shs
Average Volume716,448 shs
Market Capitalization$1.73 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.03
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AIMT
CUSIPN/A
Phone650-614-5220

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.09 per share

Profitability

Net Income$-210,750,000.00

Miscellaneous

Employees228
Market Cap$1.73 billion
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive AIMT News and Ratings via Email

Sign-up to receive the latest news and ratings for AIMT and its competitors with MarketBeat's FREE daily newsletter.


Aimmune Therapeutics (NASDAQ:AIMT) Frequently Asked Questions

What is Aimmune Therapeutics' stock symbol?

Aimmune Therapeutics trades on the NASDAQ under the ticker symbol "AIMT."

How were Aimmune Therapeutics' earnings last quarter?

Aimmune Therapeutics Inc (NASDAQ:AIMT) announced its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported ($1.03) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($1.03). During the same period last year, the business earned ($0.89) EPS. View Aimmune Therapeutics' Earnings History.

When is Aimmune Therapeutics' next earnings date?

Aimmune Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Aimmune Therapeutics.

What price target have analysts set for AIMT?

8 Wall Street analysts have issued 1 year target prices for Aimmune Therapeutics' shares. Their forecasts range from $27.00 to $79.00. On average, they anticipate Aimmune Therapeutics' stock price to reach $45.75 in the next year. This suggests a possible upside of 65.9% from the stock's current price. View Analyst Price Targets for Aimmune Therapeutics.

What is the consensus analysts' recommendation for Aimmune Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aimmune Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aimmune Therapeutics.

What are Wall Street analysts saying about Aimmune Therapeutics stock?

Here are some recent quotes from research analysts about Aimmune Therapeutics stock:
  • 1. According to Zacks Investment Research, "Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. " (11/7/2019)
  • 2. Stifel Nicolaus analysts commented, "We continue to expect the focus of the Adcom to be on safety – risk of anaphylaxis and use of epinephrine – which is not new" news and we think also around the long-term use/safety of AR101 in patients (i.e. EoE). We think this should provide some relief for shares today as the investors’ worst case" scenario in terms of the panel may be off the table as the agency struck a relatively positive tone in the docs, in our view. With the stock continuing to move up ahead of the Adcom, we think the risk/reward at these levels is less favorable once Palforzia is approved given the commercial/logistical challenges we feel lay ahead, which is core to our thesis, and the Adcom isn’t completely devoid of risk." (9/11/2019)

Has Aimmune Therapeutics been receiving favorable news coverage?

Media stories about AIMT stock have been trending positive this week, according to InfoTrie. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Aimmune Therapeutics earned a news impact score of 2.2 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Aimmune Therapeutics.

Are investors shorting Aimmune Therapeutics?

Aimmune Therapeutics saw a drop in short interest in October. As of October 31st, there was short interest totalling 11,420,000 shares, a drop of 20.9% from the September 30th total of 14,430,000 shares. Based on an average daily volume of 1,020,000 shares, the days-to-cover ratio is presently 11.2 days. Currently, 29.5% of the shares of the company are sold short. View Aimmune Therapeutics' Current Options Chain.

Who are some of Aimmune Therapeutics' key competitors?

What other stocks do shareholders of Aimmune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aimmune Therapeutics investors own include Hawkins (HWKN), Alibaba Group (BABA), CA (CA), Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Micron Technology (MU), AbbVie (ABBV), BlackRock (BLK), Amarin (AMRN) and Endologix (ELGX).

Who are Aimmune Therapeutics' key executives?

Aimmune Therapeutics' management team includes the folowing people:
  • Dr. Jayson Donald Alexander Dallas, Pres, CEO & Director (Age 51)
  • Mr. Eric H. Bjerkholt, Chief Financial Officer (Age 59)
  • Mr. Douglas T. Sheehy, Gen. Counsel & Sec. (Age 52)
  • Dr. Stephen George Dilly, Special Advisor (Age 59)
  • Dr. Daniel C. Adelman, Chief Medical Officer (Age 62)

When did Aimmune Therapeutics IPO?

(AIMT) raised $124 million in an IPO on Thursday, August 6th 2015. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Credit Suisse and Piper Jaffray served as the underwriters for the IPO.

Who are Aimmune Therapeutics' major shareholders?

Aimmune Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Rice Hall James & Associates LLC (1.20%), Emerald Advisers LLC (0.97%), Emerald Mutual Fund Advisers Trust (0.94%), Massachusetts Financial Services Co. MA (0.86%), GW&K Investment Management LLC (0.44%) and State of New Jersey Common Pension Fund D (0.19%). Company insiders that own Aimmune Therapeutics stock include Bakker Juliet Tammenoms, Daniel C Md Adelman, Douglas T Sheehy, Eric Bjerkholt, Jayson Donald Alexander Dallas, Kathryn E Falberg, Mary M Rozenman, Patrick G Enright, Stephen George Dilly and Susan E Barrowcliffe. View Institutional Ownership Trends for Aimmune Therapeutics.

Which major investors are selling Aimmune Therapeutics stock?

AIMT stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust and Mackay Shields LLC. View Insider Buying and Selling for Aimmune Therapeutics.

Which major investors are buying Aimmune Therapeutics stock?

AIMT stock was bought by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Massachusetts Financial Services Co. MA, Rice Hall James & Associates LLC, GW&K Investment Management LLC, Lisanti Capital Growth LLC, California Public Employees Retirement System, Brinker Capital Inc. and Envestnet Asset Management Inc.. Company insiders that have bought Aimmune Therapeutics stock in the last two years include Bakker Juliet Tammenoms, Eric Bjerkholt, Jayson Donald Alexander Dallas, Kathryn E Falberg and Patrick G Enright. View Insider Buying and Selling for Aimmune Therapeutics.

How do I buy shares of Aimmune Therapeutics?

Shares of AIMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Aimmune Therapeutics' stock price today?

One share of AIMT stock can currently be purchased for approximately $27.57.

How big of a company is Aimmune Therapeutics?

Aimmune Therapeutics has a market capitalization of $1.73 billion. The biotechnology company earns $-210,750,000.00 in net income (profit) each year or ($3.67) on an earnings per share basis. Aimmune Therapeutics employs 228 workers across the globe.View Additional Information About Aimmune Therapeutics.

What is Aimmune Therapeutics' official website?

The official website for Aimmune Therapeutics is http://www.aimmune.com/.

How can I contact Aimmune Therapeutics?

Aimmune Therapeutics' mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-614-5220 or via email at [email protected]


MarketBeat Community Rating for Aimmune Therapeutics (NASDAQ AIMT)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  399 (Vote Outperform)
Underperform Votes:  277 (Vote Underperform)
Total Votes:  676
MarketBeat's community ratings are surveys of what our community members think about Aimmune Therapeutics and other stocks. Vote "Outperform" if you believe AIMT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AIMT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Featured Article: Return on Investment (ROI)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel